

## DECISION OF THE ATHLETICS INTEGRITY UNIT IN THE CASE OF MS DAISY CHEROTICH

### INTRODUCTION

1. World Athletics has established the Athletics Integrity Unit ("**AIU**") whose role is to protect the integrity of the sport of Athletics, including fulfilling World Athletics' obligations as a Signatory to the World Anti-Doping Code ("the "**Code**"). World Athletics has delegated implementation of the World Athletics Anti-Doping Rules ("**ADR**") to the AIU, including but not limited to the following activities in relation to International-Level Athletes: Testing, Investigations, Results Management, Hearings, Sanctions and Appeals.
2. Ms Daisy Cherotich ("the **Athlete**") is a 26-year-old long-distance runner from Kenya<sup>1</sup>.
3. This decision is issued by the AIU pursuant to Rule 8.5.6 ADR, which provides as follows:

*"8.5.6 In the event that the Athlete or other Person either (i) admits the violation and accepts the proposed Consequences or (ii) is deemed to have admitted the violation and accepted the Consequences as per Rule 8.5.2(f), the Integrity Unit will promptly:*

- (a) issue a decision confirming the commission of the violation(s) and the imposition of the specified Consequences (including, if applicable, a justification for why the maximum potential sanction was not imposed);*
- (b) Publicly Report that decision in accordance with Rule 14;*
- (c) send a copy of the decision to the Athlete or other Person and to any other party that has a right, further to Rule 13, to appeal the decision (and any such party may, within 15 days of receipt, request a copy of the full case file pertaining to the decision)."*

### THE ATHLETE'S COMMISSION OF ANTI-DOPING RULE VIOLATIONS

4. Rule 2 ADR sets out that the following shall constitute an Anti-Doping Rule Violation:
  - "2.1 Presence of a Prohibited Substance or its Metabolites or Markers in an Athlete's Sample*  
  
*[...]*
  - 2.2 Use or Attempted Use by an Athlete of a Prohibited Substance or a Prohibited Method"*
5. On 11 January 2023, the Athlete provided a urine Sample Out-of-Competition in Kapsabet, Kenya, which was given code 1117293 (the "**Sample**").

---

<sup>1</sup> <https://worldathletics.org/athletes/kenya/daisy-cherotich-14790677>

6. On 17 February 2023, the World Anti-Doping Agency (“WADA”) accredited laboratory in Lausanne, Switzerland (the “Laboratory”) reported an Adverse Analytical Finding in the Sample based on the presence of recombinant erythropoietin (“EPO”) (the “Adverse Analytical Finding”).
7. The AIU reviewed the Adverse Analytical Finding in accordance with Article 5 of the International Standard for Results Management (“ISRM”) and determined that:
  - 7.1. the Athlete did not have a Therapeutic Use Exemption (“TUE”) that had been granted (or that would be granted) for the EPO found in the Sample; and
  - 7.2. there was no apparent departure from the International Standard for Testing and Investigations (“ISTI”) or from the International Standard for Laboratories (“ISL”) that could reasonably have caused the Adverse Analytical Finding.
8. Therefore, on 21 February 2023, the AIU notified the Athlete of the Adverse Analytical Finding in accordance with Article 5.1.2.1 of the ISRM, including that the Adverse Analytical Finding may result in Anti-Doping Rule Violations pursuant to Rule 2.1 ADR and/or Rule 2.2 ADR and of the imposition of an immediate Provisional Suspension.
9. The Athlete was also informed of her rights, inter alia, to request the B Sample analysis, to request copies of the laboratory documentation supporting the Adverse Analytical Finding and to admit the Anti-Doping Rule Violations and potentially benefit from a one-year reduction in the period of Ineligibility pursuant to Rule 10.8.1 ADR.
10. The Athlete did not reply within the given deadline.
11. On 1 March 2023, the AIU exceptionally granted the Athlete an extension until 6 March 2023 to provide her reply to the Notice of Allegation. She was reminded *inter alia* that in the absence of a response by 6 March 2023, she would be deemed to have waived her right to the B Sample analysis and to have accepted the Adverse Analytical Finding<sup>2</sup>.
12. The Athlete failed to reply within the given deadline. The AIU made several attempts to contact the Athlete (including via representatives of her Member Federation, Athletics Kenya). The Athlete failed to respond. The AIU therefore deemed that the Athlete had waived her right to the B Sample analysis and accepted the Adverse Analytical Finding.
13. Therefore, on 3 July 2023, the AIU issued the Athlete with a Notice of Charge in accordance with Rule 8.5.1 ADR and Article 7.1 ISRM confirming that she was being charged with Anti-Doping Rule Violations under Rule 2.1 ADR and Rule 2.2 ADR (“the Charge”) and that the Consequences included (i) a period of Ineligibility of four (4) years and (ii) disqualification of her results on and since 11 January 2023.

---

<sup>2</sup> On the same day, 1 March 2023, the AIU attempted to contact the Athlete by message (via WhatsApp) and by phone using the telephone number that the Athlete provided on her Doping Control Form. The Athlete failed to respond to the messages and could not be reached by phone.

14. The AIU invited the Athlete to respond to the Charge confirming how she wished to proceed by no later than 17 July 2023 and confirmed that, if the Athlete failed to challenge the AIU's assertion of the Anti-Doping Rule Violations or the Consequences, or failed to request a hearing, then she would be deemed to have waived her right to a hearing, admitted the Anti-Doping Rule Violations and accepted the Consequences set out in the Charge in accordance with Rule 8.5.2(f) ADR.
15. On 16 July 2023, the AIU received an Admission of Anti-Doping Rule Violations and Acceptance of Consequences Form signed by the Athlete.

## CONSEQUENCES

16. This is the Athlete's first Anti-Doping Rule Violation.
17. Rule 10.2 ADR specifies that the period of Ineligibility for an Anti-Doping Rule Violation under Rule 2.1 or Rule 2.2 shall be as follows:

*“10.2.1 Save where Rule 10.2.4 applies, the period of Ineligibility will be four years where:*

- (a) The anti-doping rule violation does not involve a Specified Substance or a Specified Method, unless the Athlete or other Person can establish that the anti-doping rule violation was not intentional.*
- (b) The anti-doping rule violation involves a Specified Substance or a Specified Method and the Integrity Unit can establish that the anti-doping rule violation was intentional.”*

18. EPO is a Prohibited Substance under the WADA 2023 Prohibited List under the category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. It is a Non-Specified Substance prohibited at all times.
19. The period of Ineligibility to be imposed is therefore a period of four (4) years, unless the Athlete demonstrates that the Anti-Doping Rule Violations were not intentional.
20. The Athlete has not demonstrated that the Anti-Doping Rule Violations were not intentional. Therefore, the mandatory period of Ineligibility is a period of Ineligibility of four (4) years.
21. However, Rule 10.8.1 ADR provides that an athlete potentially subject to an asserted period of Ineligibility of four (4) years may benefit from a one (1)-year reduction in the period of Ineligibility based on an early admission and acceptance of sanction:

*“10.8.1 One year reduction for certain anti-doping rule violations based on early admission and acceptance of sanction.*

*Where the Integrity Unit notifies an Athlete or other Person of an anti-doping rule violation charge that carries an asserted period of Ineligibility of four (4) or more years (including any period of Ineligibility asserted under Rule 10.4), if the Athlete or other Person admits the violation and accepts the asserted period of Ineligibility no later than 20 days after receiving the Notice of Charge, the Athlete or other Person may receive a one (1) year reduction in the period of Ineligibility asserted by the Integrity Unit. Where the Athlete or other Person receives the one (1) year reduction in the asserted period of Ineligibility under this Rule 10.8.1, no*

*further reduction in the asserted period of Ineligibility will be allowed under any other Rule.”*

22. The Athlete was issued with a Notice of Charge on 3 July 2023. On 16 July 2023, (13 days after receiving the Charge) the Athlete returned a signed Admission of Anti-Doping Rule Violations and Acceptance of Consequences Form confirming that she admitted the Anti-Doping Rule Violations and accepted the asserted period of Ineligibility.
23. The Athlete shall therefore receive a one (1) year reduction in the asserted period of Ineligibility pursuant to Rule 10.8.1 based on an early admission and acceptance of sanction.
24. On the basis that the Athlete has admitted the Anti-Doping Rule Violations under Rule 2.1 ADR and Rule 2.2 ADR, in accordance with Rule 10.2.1 ADR and the application of Rule 10.8.1 ADR, the AIU confirms by this decision the following Consequences for a first Anti-Doping Rule Violation:
  - 24.1. a period of Ineligibility of three (3) years commencing on 21 February 2023 (the date of Provisional Suspension); and
  - 24.2. disqualification of the Athlete’s results since 11 January 2023, with all resulting Consequences, including the forfeiture of any titles, awards, medals, points prizes and appearance money.
25. The Athlete has accepted the above Consequences for her Anti-Doping Rule Violations and has expressly waived her right to have those Consequences determined by the Disciplinary Tribunal at a hearing.

## PUBLICATION

26. In accordance with Rule 8.5.6(b) ADR, the AIU shall publicly report this decision on the AIU's website.

## RIGHTS OF APPEAL

27. This decision constitutes the final decision of the AIU pursuant to Rule 8.5.6 ADR.
28. Further to Rule 13.2.3 ADR, the Athlete, WADA and the Anti-Doping Agency of Kenya (“**ADAK**”) have a right of appeal against this decision to the Court of Arbitration for Sport in Lausanne, Switzerland, in accordance with the procedure set out at Rule 13.6.1 ADR.
29. If an appeal is filed against this decision by WADA or ADAK, the Athlete will be entitled to exercise her right of cross-appeal in accordance with Rule 13.2.4 ADR.

Monaco, 19 October 2023